RZLT Stock Overview
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States.
Notes are coming soon
Rezolute, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.06|
|52 Week High||US$5.01|
|52 Week Low||US$1.34|
|1 Month Change||4.04%|
|3 Month Change||23.72%|
|1 Year Change||-47.31%|
|3 Year Change||-61.53%|
|5 Year Change||-95.41%|
|Change since IPO||-99.69%|
Recent News & Updates
|RZLT||US Biotechs||US Market|
Return vs Industry: RZLT underperformed the US Biotechs industry which returned 10.5% over the past year.
Return vs Market: RZLT underperformed the US Market which returned -8.5% over the past year.
|RZLT Average Weekly Movement||12.2%|
|Biotechs Industry Average Movement||12.2%|
|Market Average Movement||7.0%|
|10% most volatile stocks in US Market||17.3%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: RZLT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: RZLT's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company’s lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema.
Rezolute, Inc. Fundamentals Summary
|RZLT fundamental statistics|
Is RZLT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RZLT income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.17|
|Net Profit Margin||0.00%|
How did RZLT perform over the long term?See historical performance and comparison